Risk/Reward Rating: Negative
GoodRx Holdings, Inc. (NASDAQ: GDRX) continues to report excellent revenue performance through the first half of 2021 with growth of 31% compared to the first half of 2020. Since its founding in 2011, the company has successfully built a leading brand within the prescription drug market among consumers, healthcare providers, and drug manufacturers. The brand equity to date has been built on enabling consumers to afford prescription drugs when insurance is not sufficient to cover the price or when consumers lack insurance coverage altogether. In essence, the GoodRx brand penetrated the marketplace under the company’s original mission: “to help Americans get the healthcare they need at a price they can afford.”
Business Model Shift
Since the company’s IPO on September 23, 2020, GoodRx has been executing a material shift in its mission and business model. In addition to the original affordability-focused mission statement, the company has added and is now implementing the following vision: “We are building the leading, consumer-focused digital healthcare platform in the United States.”
The business model shift is from a narrow prescription drug pricing value proposition to a more holistic subscription and fee-based digital healthcare platform integrating consumers, healthcare providers, and drug manufacturers. The platform encompasses not just pricing alternatives but information and service delivery. It is a bold strategy that carries a heightened level of execution risk and, if successful, offers a much larger reward for GoodRx shareholders over the long term.
The prescription drug transaction market in the United States is an enormous addressable market opportunity. GoodRx is now adding the massive healthcare service provider sector and drug manufacturer marketing and distribution opportunity to its total addressable market. GoodRx will face stiff competition for its broadening platform approach. The enormity of the opportunity is coveted by most industry players and increasingly by technology-focused entrants such as Amazon (NASDAQ: AMZN), who is the ultimate competitor.
To build the case for GoodRx given the transformation taking place, we must first understand how the company arrived at this juncture and the trajectory it is currently on.
Continue reading this report with a stoxdox membership.